CAH — Cardinal Health, Inc.

Cardinal Health, Inc. (CAH) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Revenue: Increased 22% to $64 billion, driven by strong demand across all segments.
• Gross Profit: Grew 22% to $2.3 billion.
• SG&A Expenses: Increased 14% to $1.5 billion, reflecting cost management efforts.
• Operating Earnings: Rose 37% year-over-year.
• EPS: Increased by 36% to $2.55.
• Adjusted Free Cash Flow: Generated $1.3 billion in Q1.
• Cash Position: Ended the quarter with $4.6 billion, including $1 billion from bond issuance.

2. Strategic Updates and Business Highlights

• Pharmaceutical and Specialty Solutions: Led growth with a 23% revenue increase to $59 billion, driven by strong brand and specialty pharmaceutical sales, including a notable contribution from GLP-1 sales.
• Acquisition of Solaris Health: Expected to close shortly, enhancing the Specialty Alliance platform and adding significant scale in urology.
• Integration Progress: Successful integration of ADS into at-Home Solutions, contributing to strong demand and operational synergies.
• GMPD Segment: Revenue grew 2% to $3.2 billion, with a focus on mitigating tariff impacts and improving operational performance.
• Other Growth Businesses: Revenue in this segment increased 38% to $1.6 billion, with strong performances in Nuclear and Precision Health Solutions and OptiFreight Logistics.

3. Forward Guidance and Outlook

• EPS Guidance: Raised to a range of $9.65 to $9.85 for the fiscal year, reflecting 17% to 20% growth year-over-year.
• Adjusted Free Cash Flow Guidance: Increased to $3 billion to $3.5 billion for the full year.
• Pharmaceutical Revenue Growth: Updated guidance to 15% to 17%, up from 11% to 13%.
• GMPD Revenue Growth: Expected to remain at 2% to 4%, with anticipated tariff costs impacting profitability in Q2.

4. Bad News, Challenges, or Points of Concern

• Tariff Costs: Expected to increase in Q2, which may pressure GMPD profitability.
• COVID Vaccine Distribution: Continued to be a headwind, impacting year-over-year comparisons.
• Market Dynamics: While demand remains strong, the company is cautious about not assuming outsized growth trends, indicating potential deceleration in the latter half of the fiscal year.
• Competitive Landscape: Ongoing competitive pressures in the GMPD segment, particularly following a competitor's divestiture.

5. Notable Q&A Insights

• Customer Dynamics: Management noted that while they are benefiting from increased share with customers like CVS, the impact of Rite Aid's closure remains uncertain.
• Policy Changes: Management expressed optimism about potential regulatory changes that could enhance access to biosimilars, though they remain cautious about the specifics.
• MSO Growth: The MSO platforms are expected to contribute significantly to growth, with a focus on autoimmune, urology, and oncology specialties.
• Generic Drug Performance: Strong demand for generics was noted, driven by volume rather than pricing, with expectations of continued growth from new product launches.

Overall, Cardinal Health reported a robust start to fiscal 2026, with strong financial performance across its segments and strategic initiatives aimed at sustaining growth. However, challenges such as tariff impacts and competitive pressures remain areas of focus for management.